ZA200710606B - New 2-azetidinone derivatives as cholestrol absorption inhibitors for the treatment of hyperlipidaemic conditions - Google Patents
New 2-azetidinone derivatives as cholestrol absorption inhibitors for the treatment of hyperlipidaemic conditionsInfo
- Publication number
- ZA200710606B ZA200710606B ZA200710606A ZA200710606A ZA200710606B ZA 200710606 B ZA200710606 B ZA 200710606B ZA 200710606 A ZA200710606 A ZA 200710606A ZA 200710606 A ZA200710606 A ZA 200710606A ZA 200710606 B ZA200710606 B ZA 200710606B
- Authority
- ZA
- South Africa
- Prior art keywords
- cholestrol
- treatment
- new
- absorption inhibitors
- azetidinone derivatives
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical class O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title 1
- 230000003516 hyperlipidaemic effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0501468 | 2005-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200710606B true ZA200710606B (en) | 2008-12-31 |
Family
ID=37570731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200710606A ZA200710606B (en) | 2005-06-22 | 2007-12-05 | New 2-azetidinone derivatives as cholestrol absorption inhibitors for the treatment of hyperlipidaemic conditions |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100048530A1 (ja) |
EP (1) | EP1896458A4 (ja) |
JP (1) | JP2008546770A (ja) |
KR (1) | KR20080033265A (ja) |
CN (1) | CN101223163A (ja) |
AR (1) | AR057383A1 (ja) |
AU (1) | AU2006259894A1 (ja) |
BR (1) | BRPI0611616A2 (ja) |
CA (1) | CA2609990A1 (ja) |
EC (1) | ECSP088103A (ja) |
IL (1) | IL187738A0 (ja) |
MX (1) | MX2007016486A (ja) |
NO (1) | NO20076196L (ja) |
RU (1) | RU2007147346A (ja) |
TW (1) | TW200726760A (ja) |
UY (1) | UY29615A1 (ja) |
WO (1) | WO2006137793A1 (ja) |
ZA (1) | ZA200710606B (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1699759B1 (en) * | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
UY29607A1 (es) | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
AR057072A1 (es) | 2005-06-22 | 2007-11-14 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
CA2675312A1 (en) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
CA2754384A1 (en) | 2009-03-06 | 2010-09-10 | Lipideon Biotechnology Ag | Pharmaceutical hypocholesterolemic compositions |
US8785608B2 (en) | 2009-08-26 | 2014-07-22 | Sanofi | Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3300B (en) * | 1992-12-23 | 1995-06-26 | Schering Corp | Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor |
US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
MXPA04002572A (es) * | 2001-09-21 | 2004-05-31 | Schering Corp | Metodos para el tratamiento o prevencion de inflamacion vascular usando inhibidores de absorcion de esterol. |
US7053080B2 (en) * | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US6761509B2 (en) * | 2002-07-26 | 2004-07-13 | Jan Erik Jansson | Concrete module for retaining wall and improved retaining wall |
US6960047B2 (en) * | 2002-08-02 | 2005-11-01 | Innovative Technology Application, Inc. | Protection barrier apparatus |
ATE406364T1 (de) * | 2003-03-07 | 2008-09-15 | Schering Corp | Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia |
US7002008B2 (en) * | 2003-06-16 | 2006-02-21 | Bomi Patel Framroze | Process for the preparation of 1-(4-fluorophenyl)-4(S)-(4-hydroxyphenyl)-azetidin-2-one |
JP2007510659A (ja) * | 2003-11-05 | 2007-04-26 | シェーリング コーポレイション | 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置 |
AU2004308332B2 (en) * | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
EP1699759B1 (en) * | 2003-12-23 | 2010-10-20 | AstraZeneca AB | Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
KR100725758B1 (ko) * | 2004-03-30 | 2007-06-08 | 삼성광주전자 주식회사 | 전동 송풍기 및 이를 이용한 자동차용 전동 과급기 |
US20060046996A1 (en) * | 2004-08-31 | 2006-03-02 | Kowa Co., Ltd. | Method for treating hyperlipidemia |
WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
US20070049748A1 (en) * | 2005-08-26 | 2007-03-01 | Uppala Venkata Bhaskara R | Preparation of ezetimibe |
TW200806623A (en) * | 2005-10-05 | 2008-02-01 | Merck & Co Inc | Anti-hypercholesterolemic compounds |
US7498431B2 (en) * | 2005-12-01 | 2009-03-03 | Bomi Patel Framroze | Process for the preparation of chiral azetidinones |
AR060623A1 (es) * | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
US20080070890A1 (en) * | 2006-09-15 | 2008-03-20 | Burnett Duane A | Spirocyclic Azetidinone Compounds and Methods of Use Thereof |
CA2675312A1 (en) * | 2007-03-06 | 2008-09-12 | Teijin Pharma Limited | 1-biarylazetidinone derivative |
-
2006
- 2006-06-20 AR ARP060102615A patent/AR057383A1/es not_active Application Discontinuation
- 2006-06-21 MX MX2007016486A patent/MX2007016486A/es not_active Application Discontinuation
- 2006-06-21 US US11/993,479 patent/US20100048530A1/en not_active Abandoned
- 2006-06-21 CA CA002609990A patent/CA2609990A1/en not_active Abandoned
- 2006-06-21 RU RU2007147346/04A patent/RU2007147346A/ru not_active Application Discontinuation
- 2006-06-21 WO PCT/SE2006/000762 patent/WO2006137793A1/en active Application Filing
- 2006-06-21 JP JP2008518084A patent/JP2008546770A/ja not_active Withdrawn
- 2006-06-21 AU AU2006259894A patent/AU2006259894A1/en not_active Abandoned
- 2006-06-21 CN CNA2006800262826A patent/CN101223163A/zh active Pending
- 2006-06-21 BR BRPI0611616-7A patent/BRPI0611616A2/pt not_active Application Discontinuation
- 2006-06-21 KR KR1020087001049A patent/KR20080033265A/ko not_active Application Discontinuation
- 2006-06-21 UY UY29615A patent/UY29615A1/es not_active Application Discontinuation
- 2006-06-21 EP EP06747951A patent/EP1896458A4/en not_active Withdrawn
- 2006-06-22 TW TW095122510A patent/TW200726760A/zh unknown
-
2007
- 2007-11-28 IL IL187738A patent/IL187738A0/en unknown
- 2007-12-03 NO NO20076196A patent/NO20076196L/no not_active Application Discontinuation
- 2007-12-05 ZA ZA200710606A patent/ZA200710606B/xx unknown
-
2008
- 2008-01-11 EC EC2008008103A patent/ECSP088103A/es unknown
Also Published As
Publication number | Publication date |
---|---|
UY29615A1 (es) | 2007-01-31 |
CN101223163A (zh) | 2008-07-16 |
AU2006259894A1 (en) | 2006-12-28 |
EP1896458A4 (en) | 2010-03-10 |
MX2007016486A (es) | 2008-03-07 |
ECSP088103A (es) | 2008-02-20 |
CA2609990A1 (en) | 2006-12-28 |
TW200726760A (en) | 2007-07-16 |
KR20080033265A (ko) | 2008-04-16 |
EP1896458A1 (en) | 2008-03-12 |
US20100048530A1 (en) | 2010-02-25 |
IL187738A0 (en) | 2008-08-07 |
WO2006137793A1 (en) | 2006-12-28 |
BRPI0611616A2 (pt) | 2011-05-31 |
AR057383A1 (es) | 2007-12-05 |
RU2007147346A (ru) | 2009-07-27 |
NO20076196L (no) | 2008-02-29 |
JP2008546770A (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200710606B (en) | New 2-azetidinone derivatives as cholestrol absorption inhibitors for the treatment of hyperlipidaemic conditions | |
IL187740A0 (en) | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | |
IL187741A0 (en) | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions | |
IL187737A0 (en) | New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions | |
IL187739A0 (en) | New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases | |
IL185016A0 (en) | Compounds for the treatment of proliferative disorders | |
IL187736A0 (en) | Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia | |
IL208607A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
IL191832A0 (en) | Pyridiazinone derivatives for the treatment of tumours | |
ZA200802064B (en) | Method for the treatment of acne | |
HK1115341A1 (en) | Composition for treating mental health disorders | |
ZA200803440B (en) | Compounds for the treatment of metabolic disorders | |
PT2056814E (pt) | Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase | |
SI2024368T1 (sl) | Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine | |
ZA200708033B (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
PL1959957T3 (pl) | Pochodne pirymidyloaminobenzamidu do leczenia neurowłókniakowatości | |
HK1097831A1 (en) | Benzopyran compounds useful for the treatment of arrhytmia | |
EP1890711A4 (en) | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES | |
GB0515035D0 (en) | Treatment of atherosclerotic conditions | |
EP1942909A4 (en) | METHODS OF TREATING RESPIRATORY DISORDERS | |
IL188127A0 (en) | Methods for treating demyelination disorders | |
HU0500947D0 (en) | Composition for treatment of paradontosis | |
HUP0500948A2 (en) | Composition for treatment of diabeticus paradontosis | |
IL188104A0 (en) | Compounds useful for treating bipolar disorders | |
HUP0501153A2 (en) | New beta secretase inhibitor compounds usefules for the treatment of nervous system |